Role of neutrophils in BCG immunotherapy for bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 4, 2008, Pages 341-345

  Simons, Mark P ^a   O'Donnell, Michael A ^a   Griffith, Thomas S ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

BCG; Mycobacterium; Neutrophil; PMN; TRAIL

Indexed keywords

BCG VACCINE; INTERLEUKIN 8; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; HUMAN; MALE; MOLECULAR RECOGNITION; MYCOBACTERIUM BOVIS; NEUTROPHIL; PRIORITY JOURNAL; REVIEW;

BCG VACCINE; HUMANS; NEUTROPHILS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; URINARY BLADDER NEOPLASMS;

EID: 45849112914     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.11.031     Document Type: Review

References (32)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Utz D.C., and Farrow G.M. Management of carcinoma in situ of the bladder: The case for surgical management. Urol Clin North Am 7 (1980) 533-541
3. Morales A., Eidinger D., and Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180-183
4. Schamhart D.H., de Boer E.C., de Reijke T.M., et al. Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: Their practical use. Eur Urol 37 Suppl 3 (2000) 16-23
5. Prescott S., James K., Hargreave T.B., et al. Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147 (1992) 1636-1642
6. Lage J.M., Bauer W.C., Kelley D.R., et al. Histological parameters and pitfalls in the interpretation of bladder biopsies in Bacillus Calmette-Guerin treatment of superficial bladder cancer. J Urol 135 (1986) 916-919
7. Ludwig A.T., Moore J.M., Luo Y., et al. Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64 (2004) 3386-3390
8. Simons M.P., Moore J.M., Kemp T.J., et al. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun 75 (2007) 1265-1271
9. Crispen R. History of BCG and its substrains. Prog Clin Biol Res 310 (1989) 35-50
10. Becich M.J., Carroll S., and Ratliff T.L. Internalization of Bacille Calmette-Guerin by bladder tumor cells. J Urol 145 (1991) 1316-1324
11. Luo Y., Szilvasi A., Chen X., et al. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin Diagn Lab Immunol 3 (1996) 761-768
12. Kavoussi L.R., Brown E.J., Ritchey J.K., et al. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85 (1990) 62-67
13. Hedges S., Agace W., Svensson M., et al. Uroepithelial cells are part of a mucosal cytokine network. Infect Immun 62 (1994) 2315-2321
14. Thalmann G.N., Dewald B., Baggiolini M., et al. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: A potential prognostic factor of tumor recurrence and progression. J Urol 158 (1997) 1340-1344
15. Thalmann G.N., Sermier A., Rentsch C., et al. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164 (2000) 2129-2133
16. Shapiro A., Lijovetzky G., and Pode D. Changes of the mucosal architecture and of urine cytology during BCG treatment. World J Urol 6 (1988) 61-68
17. de Boer E.C., De Jong W.H., Van der Meijden A.P., et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin. Cancer Immunol Immunother 33 (1991) 411-416
18. Godaly G., Proudfoot A.E., Offord R.E., et al. Role of epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in Escherichia coli-induced transuroepithelial neutrophil migration. Infect Immun 65 (1997) 3451-3456
19. Kemp T.J., Ludwig A.T., Earel J.K., et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 106 (2005) 3474-3482
20. Tecchio C., Huber V., Scapini P., et al. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103 (2004) 3837-3844
21. Koga Y., Matsuzaki A., Suminoe A., et al. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): A novel mechanism of antitumor effect by neutrophils. Cancer Res 64 (2004) 1037-1043
22. Cassatella M.A., Huber V., Calzetti F., et al. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J Leukoc Biol 79 (2006) 123-132
23. Suttmann H., Riemensberger J., Bentien G., et al. Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66 (2006) 8250-8257
24. Kamohara H., Matsuyama W., Shimozato O., et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology 111 (2004) 186-194
25. Alexandroff A.B., Jackson A.M., O'Donnell M.A., et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353 (1999) 1689-1694
26. Yamamura Y., Azuma I., Taniyama T., et al. Immunotherapy of cancer with cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: Experimental and clinical results. Ann NY Acad Sci 277 (1976) 209-227
27. Filion M.C., and Phillips N.C. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin Investig Drugs 10 (2001) 2157-2165
28. Borregaard N., Heiple J.M., Simons E.R., et al. Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: Translocation during activation. J Cell Biol 97 (1983) 52-61
29. Bohle A., Nowc C., Ulmer A.J., et al. Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical Bacillus Calmette-Guerin immunotherapy. J Urol 144 (1990) 59-64
30. Jackson A.M., Alexandroff A.B., Kelly R.W., et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99 (1995) 369-375
31. Joudi F.N., Smith B.J., and O'Donnell M.A. Final results from a national multicenter Phase II trial of combination Bacillus Calmette-Guerin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
32. Faurschou M., and Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 5 (2003) 1317-1327